Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Oct 2013 Biomarkers information updated
- 09 Aug 2011 Planned End Date changed from 1 Jan 2012 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 04 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.